Longtitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine

John M. Kovarik, Barry D. Kahan, Bruce Kaplan, Marc Lorber, Michael Winkler, Marisel Rouilly, Christophe Gerbeau, Natalie Cambon, Robert Boger, Christiane Rordorf

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Objective: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. Methods: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. Everolimus dose-proportionality and stability over time were assessed in the context of linear regression and ANOVA models. Everolimus exposure-response relationships between area under the blood concentration-time curve (AUC) and changes in platelets, leukocytes, and lipids were explored with the median-effect model. Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. Results: Everolimus steady state was reached on or before day 7, with a median 3-fold accumulation of drug exposure compared with that after the first postoperative dose. Both steady-state maximum concentration and AUC were dose proportional over the full dose range when assessed on day 1, as well as for the full duration of the study at steady state. There was evidence for longitudinal stability in AUC of everolimus during the course of the study. The interindividual pharmacokinetic variability for AUC was 85.4% and intraindividual, interoccasion variability was 40.8%. Age (range, 17-69 years), weight (range, 49-106 kg), and sex (65 men and 36 women) were not significant contributors to variability. There was an increasing incidence of transient thrombocytopenia (9/L) with increasing everolimus AUC (P = .03). Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). Conclusions: Everolimus exhibited dose-proportional, stable exposure during the first post-transplant year. For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)48-56
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Cyclosporine
Pharmacokinetics
Transplants
Kidney
Area Under Curve
Everolimus
Transplant Recipients
Analysis of Variance
Prednisone
Double-Blind Method
Thrombocytopenia
Tablets
Allografts
Linear Models
Leukocytes
Blood Platelets
Transplantation
Lipids
Weights and Measures
Incidence

ASJC Scopus subject areas

  • Pharmacology

Cite this

Longtitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year : Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. / Kovarik, John M.; Kahan, Barry D.; Kaplan, Bruce; Lorber, Marc; Winkler, Michael; Rouilly, Marisel; Gerbeau, Christophe; Cambon, Natalie; Boger, Robert; Rordorf, Christiane.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 1, 2001, p. 48-56.

Research output: Contribution to journalArticle

Kovarik, John M. ; Kahan, Barry D. ; Kaplan, Bruce ; Lorber, Marc ; Winkler, Michael ; Rouilly, Marisel ; Gerbeau, Christophe ; Cambon, Natalie ; Boger, Robert ; Rordorf, Christiane. / Longtitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year : Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. In: Clinical Pharmacology and Therapeutics. 2001 ; Vol. 69, No. 1. pp. 48-56.
@article{79ef208e691e40a9827f74ac8bb19f98,
title = "Longtitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine",
abstract = "Objective: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. Methods: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. Everolimus dose-proportionality and stability over time were assessed in the context of linear regression and ANOVA models. Everolimus exposure-response relationships between area under the blood concentration-time curve (AUC) and changes in platelets, leukocytes, and lipids were explored with the median-effect model. Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. Results: Everolimus steady state was reached on or before day 7, with a median 3-fold accumulation of drug exposure compared with that after the first postoperative dose. Both steady-state maximum concentration and AUC were dose proportional over the full dose range when assessed on day 1, as well as for the full duration of the study at steady state. There was evidence for longitudinal stability in AUC of everolimus during the course of the study. The interindividual pharmacokinetic variability for AUC was 85.4{\%} and intraindividual, interoccasion variability was 40.8{\%}. Age (range, 17-69 years), weight (range, 49-106 kg), and sex (65 men and 36 women) were not significant contributors to variability. There was an increasing incidence of transient thrombocytopenia (9/L) with increasing everolimus AUC (P = .03). Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). Conclusions: Everolimus exhibited dose-proportional, stable exposure during the first post-transplant year. For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.",
author = "Kovarik, {John M.} and Kahan, {Barry D.} and Bruce Kaplan and Marc Lorber and Michael Winkler and Marisel Rouilly and Christophe Gerbeau and Natalie Cambon and Robert Boger and Christiane Rordorf",
year = "2001",
doi = "10.1067/mcp.2001.112969",
language = "English (US)",
volume = "69",
pages = "48--56",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Longtitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year

T2 - Pharmacokinetics, exposure-response relationships, and influence on cyclosporine

AU - Kovarik, John M.

AU - Kahan, Barry D.

AU - Kaplan, Bruce

AU - Lorber, Marc

AU - Winkler, Michael

AU - Rouilly, Marisel

AU - Gerbeau, Christophe

AU - Cambon, Natalie

AU - Boger, Robert

AU - Rordorf, Christiane

PY - 2001

Y1 - 2001

N2 - Objective: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. Methods: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. Everolimus dose-proportionality and stability over time were assessed in the context of linear regression and ANOVA models. Everolimus exposure-response relationships between area under the blood concentration-time curve (AUC) and changes in platelets, leukocytes, and lipids were explored with the median-effect model. Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. Results: Everolimus steady state was reached on or before day 7, with a median 3-fold accumulation of drug exposure compared with that after the first postoperative dose. Both steady-state maximum concentration and AUC were dose proportional over the full dose range when assessed on day 1, as well as for the full duration of the study at steady state. There was evidence for longitudinal stability in AUC of everolimus during the course of the study. The interindividual pharmacokinetic variability for AUC was 85.4% and intraindividual, interoccasion variability was 40.8%. Age (range, 17-69 years), weight (range, 49-106 kg), and sex (65 men and 36 women) were not significant contributors to variability. There was an increasing incidence of transient thrombocytopenia (9/L) with increasing everolimus AUC (P = .03). Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). Conclusions: Everolimus exhibited dose-proportional, stable exposure during the first post-transplant year. For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.

AB - Objective: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. Methods: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. Everolimus dose-proportionality and stability over time were assessed in the context of linear regression and ANOVA models. Everolimus exposure-response relationships between area under the blood concentration-time curve (AUC) and changes in platelets, leukocytes, and lipids were explored with the median-effect model. Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. Results: Everolimus steady state was reached on or before day 7, with a median 3-fold accumulation of drug exposure compared with that after the first postoperative dose. Both steady-state maximum concentration and AUC were dose proportional over the full dose range when assessed on day 1, as well as for the full duration of the study at steady state. There was evidence for longitudinal stability in AUC of everolimus during the course of the study. The interindividual pharmacokinetic variability for AUC was 85.4% and intraindividual, interoccasion variability was 40.8%. Age (range, 17-69 years), weight (range, 49-106 kg), and sex (65 men and 36 women) were not significant contributors to variability. There was an increasing incidence of transient thrombocytopenia (9/L) with increasing everolimus AUC (P = .03). Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). Conclusions: Everolimus exhibited dose-proportional, stable exposure during the first post-transplant year. For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.

UR - http://www.scopus.com/inward/record.url?scp=0034746371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034746371&partnerID=8YFLogxK

U2 - 10.1067/mcp.2001.112969

DO - 10.1067/mcp.2001.112969

M3 - Article

C2 - 11180038

AN - SCOPUS:0034746371

VL - 69

SP - 48

EP - 56

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -